Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Head and Neck Oncology
  •  Immunotherapy
  •  Kidney Cancer
  •  Breast Cancer
  •  Central Nervous System Tumors
  •  Immunology
  •  Blood Cancer
  •  Bladder Cancer


Citation: Clin Oncol. 2017;2(1):1208.DOI: 10.25107/2474-1663.1208

Hepatic Artery Infusion for Recurrent or Chemo Resistant Hepatic Malignancy

Wanebo HJ, Sanikommu SR, Taneja C, Begossi G, Belliveau J and Rathore R

Roger Williams Medical Center, USA
Department of Surgery, Case Western Medical Center, USA
Rhode Island Hospital, USA
Alta Bates Summit Medical Center, USA
Division of Surgical Oncology, Landmark Medical Center, USA
Department of Medical Oncology, Roger Williams Medical Center, USA

*Correspondance to: Wanebo HJ 

 PDF  Full Text Review Article | Open Access


Background: Previously treated Hepatic Colorectal Metastases (CRC) and advanced Hepato Cellular Cancer (HCC) are tumor challenges frequently unresponsive to systemic Chemo Therapy (CT). We reviewed survival outcome in chemo resistant/high risk patients following Hepatic Artery Infusion (HAI) in 21 CRC pts, 10 HCC pts, and 6 miscellaneous metastatic cancers.
Methods: Patient groups: 21 CRC pts, (16M, 5F), mean age 63, 16 had metachronous (DFI-17 mos), and 5 Synchronous CA; liver extent: 76% multiple (>5) mets or extensive bilateral, CEA (ng/m), >100, 8 pts >50 (3pts) and, NA - 7 pts. Previous CT: FU/LV (11 pts), Oxaliplatin (OX) or Irinotecan (IR) 10 pts. Liver surgery: Partial Resection/RFA - 9 pts. HCC 9 pts, cholangio CA 1 pt, M/F 5/5, average age 63. Previous RX Hepatic lobectomy + HAI were done in metastatic lung (1), Breast (1), advanced gallbladder (GBCA) (T3-4) (2 pts); HAI alone was done in Br CA (1) carcinoid (1). Treatment Protocols: CRC Protocol: HAI-FUDR 12-15mg/kg/d, dexamethasone 2mg/kg/d, Leukovorin 20mg/m2/d (14 d) plus bolus infusion (d1), Oxaliplatin (OX) 130mg/m2 (or Cisplatin (CIS) 100mg m2 d1); Systemic RX: d20-30. OX I>V. 130mg/m2, capecitabine 750-1000mg/m2/d x 10 days (also used in Miscel.Grp.). HCC Protocol: HAI-14 d as in CRC Protocol. Bolus infusion d1- doxorubicin 75mg/m2 or OX or CIS as in CRC schema.
Results: CRC: OS-CRC post start HAI was 17 mos, (2yr/5yr = 27%/6%). HCC OS was 7 mos. Median (3-12 mos in 9 evaluable pts; 1 HCC pt, with recurrence 2 yr. post hepatectomy was treated over 3.5 yrs. with HAI + RFA/TACE - (OS- 67mos). Miscellaneous group included lung (11 mos), Br CA (23, 9 mo) adv. carcinoid (3 mos), GBCA -2 pts >60 mos). Complications included infected pocket (2 pts) and duodenal fistula (1 pt).
Conclusion: Hepatic artery infusion alternating with systemic chemotherapy has apparent survival benefit in selected patients with persistent or progressive chemo resistant cancer from metastatic CRC, HCC or selected cancers (breast, lung, liver, gallbladder cancer) and warrants further study.


Cite the Article:

Wanebo HJ, Sanikommu SR, Taneja C, Begossi G, Belliveau J, Rathore R. Hepatic Artery Infusion for Recurrent or Chemo Resistant Hepatic Malignancy. Clin Oncol. 2017; 2: 1208.

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Delivered Dose Verification for Lung Cancer Stereotactic Body Radiotherapy Using Cone-Beam CT
 Abstract  PDF  Full Text
Outcome of Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia Following Single Agent Induction with Hypomethylation
 PDF  Full Text
View More...